Study claims anti-smoking medication is risky

Whereas smoking can be a well-being endanger, it now might seem giving up could be dangerous.
Chantix is definitely one of many products or services on the market to guide smokers quit. The drug, that you can buy in South Africa , has, according to a study published in the Canadian Medical Association Journal, been noticed to increase the potential risk of cardiovascular-related conditions similar to heart attacks and strokes by 72%.As its scientific name, Vareniclin, being formulated by Pfizer. It was also bring down into question for probable psychiatric side-effects for example psychosis, depression and suicidal behavior - which are not entirely unusual for most anti-smoking drugs. But Pfizer South Africa said it absolutely was worried about the reliability of the study.

"The medicine's permit by regulatory resources all over the world reveals its importance as a possible useful and correct treatment solution for adult smokers planning to give up smoking," said public affairs director Leigh Gunkel-Keuler.


Pfizer South Africa said its own safety data, including a critique of 7375 people, has not established a higher cardiovascular risk associated with Chantix.

National Council Against Smoking's Dr Yussuf Saloojee mentioned: "Chantix comes with substantial side-effects. The council has never, however, said customers certainly do not use it."